This is an unprecedented time. It is the dedication of healthcare workers that will lead us through this crisis. Thank you for everything you do.
COVID-19 Resource Center

      Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.
    Black Friday Special! 10% off CME packages (up to $545 in savings). Use code BLACKFRIDAY

    Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria

    Determines if immediate therapy for follicular lymphoma is required.
    When to Use
    Pearls/Pitfalls
    Why Use

    The criteria can help identify those patients with follicular lymphoma at higher risk for rapid disease progression and in whom immediate therapy may be needed.

    • This tool is best used as an instantaneous assessment of a patient’s disease burden. Ultimately, clinical judgement and comprehensive review of the patient’s previous workup are critical to make this assessment.
    • For overall prognosis, the FLIPI can risk stratify further than the GELF criteria.

    The GELF criteria is easy to use with information most providers will already have available. Clinical evaluation, laboratory testing, and imaging are all that is needed to determine who has a high tumor burden based on the GELF criteria.

    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Pauline Brice

    About the Creator

    Pauline Brice, MD, is a hematologist at Hopital Saint-Louis in Paris, France. She is a member of the scientific council for GELA (Groupe d'Etude des Lymphomes de l'Adulte).

    To view Dr. Pauline Brice's publications, visit PubMed

    Are you Dr. Pauline Brice? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Pauline Brice
    Are you Dr. Pauline Brice?
    Also from MDCalc...
    Content Contributors